BVAXF
BioVaxys Technology Corp.·Healthcare
0.05
14.556%(+0.01)
Market ClosedLast Updated: — ET
52W L: $0.0352W H: $0.40
BVAXF NEWS
thenewswire.com
Mar 31
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
VANCOUVER, BC, March 31, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB0) (OTCQB: BVAXF) (“ BioVaxys ” or the “ Company ”) is providing this bi-weekly update on the status of the management cease trade order granted on March 3, 2026 (the “ MCTO ”), by its principal regulator, the British Columbia Securities Commission (the “ BCSC ”) under National Policy 12-203 – Management Cease Trade Orders (“ NP 12-203 ”). The Company announced on March 3, 2026 (the “ Default Announcement ”), that it was unable to file its audited annual financial statements for the year ended October 31, 2025, the related management's discussion and analysis, and its Form 52-109FV1 CEO and CFO certifications of annual filings (collectively the “ Annual Filings ”). Under National Instrument 51-102 - Continuous Disclosure Obligations , the Annual Filings were required to be made not later than February 28, 2026. The Company is actively working with its auditor, Dale Matheson Carr-Hilton LaBonte LLP, to complete the Annual Filings, which will be filed as soon as possible. As previously stated, subject to current conditions remaining the same, the Company remains confident in its ability to complete the Annual Filings by April 28, 2026.
thenewswire.com
Mar 17
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update
VANCOUVER, BC, March 17, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“ BioVaxys ” or the “ Company ”) is providing this bi-weekly update on the status of the management cease trade order granted on March 3, 2026 (the “ MCTO ”), by its principal regulator, the British Columbia Securities Commission (the “ BCSC ”) under National Policy 12-203 – Management Cease Trade Orders (“ NP 12-203 ”). The Company announced on March 3, 2026 (the “ Default Announcement ”), that it was unable to file its audited annual financial statements for the year ended October 31, 2025, the related management's discussion and analysis, and its Form 52-109FV1 CEO and CFO certifications of annual filings (collectively the “ Annual Filings ”). Under National Instrument 51-102 - Continuous Disclosure Obligations , the Annual Filings were required to be made not later than February 28, 2026. The Company is actively working with its auditor, Dale Matheson Carr-Hilton LaBonte LLP, to complete the Annual Filings, which will be filed as soon as possible. As previously stated, subject to current conditions remaining the same, the Company remains confident in its ability to complete the Annual Filings by April 28, 2026.
thenewswire.com
Mar 3
BioVaxys Announces Application for Management Cease Trade Order
Vancouver, BC – TheNewswire - March 3rd, 2026 – BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) (“ BioVaxys ” or the “ Company ”) announces that it was unable to file its annual financial statements, management's discussion and analysis and the required certifications for the year ended October 31, 2025 (the “ Annual Filings ”) on or before the prescribed filing deadline of February 28, 2026 (the “ Annual Filing Deadline ”). The Company and the auditor have been diligently working to complete the Annual Filings, however, the Company was not able to make the required filings by the Annual Filing Deadline. The primary contributing factor to the delay was a late start to the audit as a result of the Company making changes to its accounting systems and processes. The Company believes that the audit will be completed by April 28, 2026, with the annual filings to be completed as soon as possible thereafter.
thenewswire.com
Jan 29
BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer
Reinforces Synergistic Potential and Expands Opportunity Beyond Ovarian Cancer VANCOUVER, BC – TheNewswire - January 29, 2026 / TheNewswire / - BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB:BVAXF) (“BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious disease, allergy, and other immune diseases based on its DPX™ antigen delivery and immune-educating technology platform, today announced positive findings from a Phase 2 clinical study evaluating maveropepimut-S (MVP-S) in combination with pembrolizumab and low-dose cyclophosphamide in patients with advanced or metastatic bladder cancer. These results build on the Company's recent Phase 1B/2 data in advanced ovarian cancer and further validate the potential of MVP-S to enhance checkpoint inhibitor activity across multiple solid tumor indications.
newsfilecorp.com
Jan 20
BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)
Study subject Remains in Complete Response for 3 Years Exceeds Expectations in Platinum-Resistant Ovarian Cancer Compared to Standard of Care Single-Agent Chemotherapy Vancouver, British Columbia--(Newsfile Corp. - January 20, 2026) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious disease, allergy, and other immune diseases based on its DPX™ antigen delivery and immune-educating technology platform, is pleased to announce positive preliminary results from the PESCO study, an investigator-initiated, open-label, non-randomized phase 1B/2 trial to evaluate the safety and efficacy of combination of BioVaxys' MVP-S with pembrolizumab (Keytruda™) and cyclophosphamide in patients with recurrent epithelial ovarian cancer (EOC). Led by Principal Investigator Amit Oza, MD, Director of the Cancer Clinical Research Unit, Princess Margaret Cancer Centre, University of Toronto and Chair, UHN Clinical Research Collaborative Centre, the primary study objectives were safety, recommended phase 2 dose, and clinical efficacy based on disease control rate (DCR) and overall response rate (ORR).
